Stocks and Investing Stocks and Investing
Wed, May 29, 2024
Tue, May 28, 2024

Eliana Merle Maintained (BBIO) at Strong Buy with Decreased Target to $47 on, May 28th, 2024


Published on 2024-10-28 11:39:03 - WOPRAI, Eliana Merle
  Print publication without navigation


Eliana Merle of UBS, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $51 to $47 on, May 28th, 2024.

Eliana has made no other calls on BBIO in the last 4 months.



There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 1 agrees with Eliana's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024


These are the ratings of the 5 analyists that currently disagree with Eliana


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $43 on, Monday, May 20th, 2024
  • Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $50 on, Tuesday, May 14th, 2024
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $45 on, Wednesday, March 20th, 2024
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024
Contributing Sources